Sundrug Co (9989.T) Stock Price

Sundrug Co Price

JPX·CLOSED
3,726.00JPY+67.00 (+1.81 %)
Market closed

Over the last 19 years Sundrug Co grew revenue by 8.3% annually, reaching 801.81 B JPY. Earnings per share have grown at 8.3% per year over the last 19 years. For Sundrug Co, the net margin of 3.8% is broadly stable versus 4.0% a few years ago. At today's price the dividend yield works out to roughly 3.49%. The payout ratio is around 49% of earnings. The dividend has grown at 4.3% per year over the past 19 years. The consensus 12-month price target for Sundrug Co is 5,508.00 JPY, about 47.8% above where the stock trades today. Of 13 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 4% above its 52-week low.

Sundrug Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sundrug Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sundrug Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sundrug Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sundrug Co Stock Price History
DateSundrug Co Price
8/7/20263,726.00 JPY
8/6/20263,659.00 JPY
8/5/20263,662.00 JPY
8/4/20263,678.00 JPY
8/3/20263,723.00 JPY
7/31/20263,794.00 JPY
7/30/20263,913.00 JPY
7/29/20263,975.00 JPY
7/28/20263,893.00 JPY
7/27/20263,806.00 JPY
7/24/20263,776.00 JPY
7/23/20263,775.00 JPY
7/22/20263,820.00 JPY
7/21/20263,866.00 JPY
7/17/20263,867.00 JPY
7/16/20263,816.00 JPY
7/15/20263,813.00 JPY
7/14/20263,863.00 JPY
7/13/20263,818.00 JPY
7/10/20263,791.00 JPY
7/9/20263,845.00 JPY
7/8/20263,885.00 JPY
7/7/20263,903.00 JPY
7/6/20263,872.00 JPY
7/3/20263,832.00 JPY
7/2/20263,787.00 JPY
7/1/20263,721.00 JPY
6/30/20263,811.00 JPY
6/29/20263,839.00 JPY
6/26/20263,808.00 JPY
6/25/20263,812.00 JPY
6/24/20263,779.00 JPY
6/23/20263,764.00 JPY
6/22/20263,713.00 JPY
6/19/20263,709.00 JPY
6/18/20263,730.00 JPY
6/17/20263,743.00 JPY
6/16/20263,762.00 JPY
6/15/20263,838.00 JPY
6/12/20263,809.00 JPY
6/11/20263,842.00 JPY
6/10/20263,858.00 JPY
6/9/20263,867.00 JPY
6/8/20263,875.00 JPY
6/5/20263,784.00 JPY
6/4/20263,732.00 JPY
6/3/20263,700.00 JPY
6/2/20263,667.00 JPY
6/1/20263,600.00 JPY
5/29/20263,672.00 JPY
5/28/20263,686.00 JPY
5/27/20263,638.00 JPY
5/26/20263,627.00 JPY
5/25/20263,663.00 JPY
5/22/20263,706.00 JPY
5/21/20263,706.00 JPY
5/20/20263,708.00 JPY
5/19/20263,783.00 JPY
5/18/20263,748.00 JPY
5/15/20263,732.00 JPY
5/14/20263,699.00 JPY
5/13/20263,742.00 JPY
5/12/20263,714.00 JPY
5/11/20263,737.00 JPY
5/8/20263,738.00 JPY
5/7/20263,774.00 JPY
5/1/20263,764.00 JPY
4/30/20263,773.00 JPY
4/28/20263,821.00 JPY
4/27/20263,781.00 JPY
4/24/20263,776.00 JPY
4/23/20263,776.00 JPY
4/22/20263,848.00 JPY
4/21/20263,904.00 JPY
4/20/20263,870.00 JPY
4/17/20263,831.00 JPY
4/16/20263,868.00 JPY
4/15/20263,859.00 JPY
4/14/20263,857.00 JPY
4/13/20263,825.00 JPY
4/10/20263,876.00 JPY
4/9/20263,926.00 JPY
4/8/20263,982.00 JPY
4/7/20263,962.00 JPY
4/6/20263,957.00 JPY
4/3/20263,946.00 JPY
3/27/20263,933.00 JPY
3/26/20263,922.00 JPY
3/25/20263,931.00 JPY
3/24/20263,907.00 JPY
3/23/20263,880.00 JPY
3/19/20263,918.00 JPY
3/18/20264,022.00 JPY
3/17/20263,984.00 JPY
3/16/20263,946.00 JPY
3/13/20263,959.00 JPY
3/12/20263,934.00 JPY
3/11/20264,024.00 JPY
3/9/20264,010.00 JPY
3/6/20263,987.00 JPY
3/5/20264,009.00 JPY
2/26/20264,185.00 JPY
2/25/20264,212.00 JPY
2/24/20264,264.00 JPY
2/20/20264,160.00 JPY
2/19/20264,145.00 JPY
2/18/20264,191.00 JPY
2/17/20264,144.00 JPY
2/16/20264,145.00 JPY
2/13/20264,188.00 JPY
2/12/20264,189.00 JPY
2/10/20264,236.00 JPY
2/9/20264,232.00 JPY
2/6/20264,221.00 JPY
2/5/20264,252.00 JPY
2/4/20264,184.00 JPY
2/3/20264,175.00 JPY
2/2/20264,143.00 JPY
1/30/20264,120.00 JPY
1/29/20264,084.00 JPY
1/28/20264,121.00 JPY
1/27/20264,183.00 JPY
1/26/20264,206.00 JPY
1/23/20264,267.00 JPY
1/22/20264,241.00 JPY
1/21/20264,226.00 JPY
1/20/20264,290.00 JPY
1/19/20264,194.00 JPY
1/16/20264,116.00 JPY
1/15/20264,208.00 JPY
1/14/20264,204.00 JPY
1/13/20264,208.00 JPY
1/9/20264,202.00 JPY
1/8/20264,255.00 JPY
1/7/20264,250.00 JPY
1/6/20264,295.00 JPY
1/5/20264,287.00 JPY
12/30/20254,306.00 JPY
12/29/20254,328.00 JPY
12/26/20254,298.00 JPY
12/25/20254,261.00 JPY
12/24/20254,272.00 JPY
12/23/20254,277.00 JPY
12/22/20254,235.00 JPY
12/19/20254,315.00 JPY
12/18/20254,322.00 JPY
12/17/20254,293.00 JPY
12/16/20254,294.00 JPY
12/15/20254,306.00 JPY
12/12/20254,259.00 JPY
12/11/20254,318.00 JPY
12/10/20254,361.00 JPY
12/9/20254,336.00 JPY
12/8/20254,302.00 JPY
12/5/20254,253.00 JPY
12/4/20254,256.00 JPY
12/3/20254,280.00 JPY
12/2/20254,309.00 JPY
12/1/20254,284.00 JPY
11/28/20254,331.00 JPY
11/27/20254,353.00 JPY
11/26/20254,378.00 JPY
11/25/20254,370.00 JPY
11/21/20254,435.00 JPY
11/20/20254,308.00 JPY
11/19/20254,324.00 JPY
11/18/20254,241.00 JPY
11/17/20254,259.00 JPY
11/14/20254,278.00 JPY
11/13/20254,259.00 JPY
11/12/20254,306.00 JPY
11/11/20254,319.00 JPY
11/10/20254,330.00 JPY
11/7/20254,262.00 JPY
11/6/20254,163.00 JPY
11/5/20254,165.00 JPY
11/4/20254,180.00 JPY
10/31/20254,160.00 JPY
10/30/20254,192.00 JPY
10/29/20254,092.00 JPY
10/28/20254,208.00 JPY
10/27/20254,233.00 JPY
10/24/20254,219.00 JPY
10/23/20254,233.00 JPY
10/22/20254,230.00 JPY
10/21/20254,166.00 JPY
10/20/20254,143.00 JPY
10/17/20254,092.00 JPY
10/16/20254,133.00 JPY
10/15/20254,144.00 JPY
10/14/20254,176.00 JPY
10/10/20254,155.00 JPY
10/9/20254,228.00 JPY
10/8/20254,281.00 JPY
10/7/20254,263.00 JPY
10/6/20254,235.00 JPY
10/3/20254,220.00 JPY
10/2/20254,208.00 JPY
10/1/20254,247.00 JPY
9/30/20254,337.00 JPY
9/29/20254,340.00 JPY
9/26/20254,450.00 JPY
9/25/20254,402.00 JPY
9/24/20254,418.00 JPY
9/22/20254,411.00 JPY
9/19/20254,464.00 JPY
9/18/20254,532.00 JPY
9/17/20254,541.00 JPY
9/16/20254,552.00 JPY
9/12/20254,572.00 JPY
9/11/20254,619.00 JPY
9/10/20254,623.00 JPY
9/9/20254,639.00 JPY
9/8/20254,663.00 JPY
9/5/20254,603.00 JPY
9/4/20254,645.00 JPY
9/3/20254,617.00 JPY
9/2/20254,639.00 JPY
9/1/20254,670.00 JPY
8/29/20254,629.00 JPY
8/28/20254,639.00 JPY
8/27/20254,652.00 JPY
8/26/20254,713.00 JPY
8/25/20254,739.00 JPY
8/22/20254,806.00 JPY
8/21/20254,841.00 JPY
8/20/20254,839.00 JPY
8/19/20254,812.00 JPY
8/18/20254,717.00 JPY
8/15/20254,820.00 JPY
8/14/20254,589.00 JPY
8/13/20254,690.00 JPY
8/12/20254,728.00 JPY
Access this data via the Eulerpool API
Get Free API Key

Sundrug Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
690.46 B JPY
37.45 B JPY
25.70 B JPY
Jan 1, 2024
751.78 B JPY
41.00 B JPY
29.13 B JPY
Jan 1, 2025
801.81 B JPY
44.50 B JPY
30.75 B JPY
Jan 1, 2026 (e)
841.98 B JPY
47.25 B JPY
31.40 B JPY
Jan 1, 2027 (e)
898.00 B JPY
50.39 B JPY
33.81 B JPY
Jan 1, 2028 (e)
947.75 B JPY
53.18 B JPY
36.26 B JPY
Jan 1, 2029 (e)
982.37 B JPY
55.12 B JPY
37.76 B JPY
Jan 1, 2030 (e)
1.02 T JPY
57.03 B JPY
37.64 B JPY

Sundrug Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 10:03 PM
 
REVENUET JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
DIV.JPY
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
0.500.530.560.590.620.630.650.690.750.800.840.900.950.981.021.06
13.004.896.784.235.052.682.276.438.886.665.016.655.543.653.454.57
24.6424.7424.9825.0325.0325.0024.1224.9025.1825.4525.4525.4525.4525.4525.4525.45
124.12130.75140.96147.18154.62158.55156.51171.95189.32204.09214.31228.57241.23250.05258.68270.49
33.0334.0636.0835.2336.6037.3534.0537.4541.0044.5047.2550.3953.1855.1257.0359.63
6.566.456.395.995.935.895.255.425.455.555.615.615.615.615.615.61
21.5723.3124.8323.9323.6925.3323.8525.7029.1330.7531.4033.8136.2637.7637.6439.00
31.828.086.51-3.61-1.016.91-5.837.7613.325.582.107.697.244.13-0.323.61
90.0054.5066.0067.0069.0070.0086.00107.00122.00130.00196.00235.20282.24–––
28.57-39.4421.101.522.991.4522.8624.4214.026.5650.7720.0020.00–––
120.89118.15116.95116.89116.90116.92116.92116.93116.94116.96116.96116.96116.96116.96116.96116.96
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sundrug Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sundrug Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sundrug Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sundrug Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sundrug Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sundrug Co stock margins

The Sundrug Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sundrug Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sundrug Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
25.00 %
5.89 %
3.99 %
Jan 1, 2022
24.12 %
5.25 %
3.68 %
Jan 1, 2023
24.90 %
5.42 %
3.72 %
Jan 1, 2024
25.18 %
5.45 %
3.87 %
Jan 1, 2025
25.45 %
5.55 %
3.84 %
Jan 1, 2026 (e)
25.45 %
5.61 %
3.73 %
Jan 1, 2027 (e)
25.45 %
5.61 %
3.77 %
Jan 1, 2028 (e)
25.45 %
5.61 %
3.83 %

Sundrug Co Stock Revenue, EBIT, Earnings per Share

The Sundrug Co earnings per share therefore indicates how much revenue Sundrug Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5,425.08 JPY
319.40 JPY
216.63 JPY
Jan 1, 2022
5,548.36 JPY
291.23 JPY
204.01 JPY
Jan 1, 2023
5,904.86 JPY
320.29 JPY
219.81 JPY
Jan 1, 2024
6,428.59 JPY
350.56 JPY
249.06 JPY
Jan 1, 2025
6,855.27 JPY
380.43 JPY
262.90 JPY
Jan 1, 2026 (e)
7,198.73 JPY
403.94 JPY
268.44 JPY
Jan 1, 2027 (e)
7,677.66 JPY
430.81 JPY
289.08 JPY
Jan 1, 2028 (e)
8,103.01 JPY
454.68 JPY
310.00 JPY

Sundrug Co business model & stock analysis

Sundrug Co Ltd is a Japanese company that was founded in Osaka in 1960. It started as a small pharmaceutical company that manufactured and sold over-the-counter medications and health products. Over the years, Sundrug has developed into a leading company in the Japanese health market. The business model of Sundrug is based on a comprehensive offering of health products and services. The company operates a variety of stores, including drugstores, pharmacies, supermarkets, and shopping centers, where it offers a wide range of products. The company is also involved in the manufacturing and marketing of pharmaceuticals and medical devices, and provides services such as health consultation and nursing care. One of the key divisions of Sundrug is its retail department, with its drugstores and pharmacies. Here, the company offers a wide range of over-the-counter medications, vitamins, and health products. The products range from cosmetic items to dietary supplements to enhance the well-being and health of customers. Another important division of Sundrug is the production of pharmaceutical products. The company manufactures a wide range of medications and medical devices, such as antibiotics, pain relievers, or diabetes medications. As part of its quality control, the company has a strict system for monitoring and testing its products. Sundrug is also active in the service industry and operates some hospitals and care facilities. The company offers consulting services and care services for elderly people. It operates as a non-profit organization and places great emphasis on promoting quality of life and health. The company also has a strong presence in the e-commerce sector. It operates an online platform where customers can conveniently order their health products from home. The company also offers a subscription service for regularly needed medications and products. Another important division of Sundrug is the cosmetic department. Here, the company offers a wide range of beauty products such as skin creams, shampoos, and makeup. The company follows the approach of meeting the needs of customers and offering products suitable for different age groups and skin types. Today, Sundrug is a leading company in the Japanese health market. Over the years, it has built a strong brand image and is known for its high-quality products and excellent services. The company places great emphasis on promoting health and well-being and strives to play a leading role in this market.

Sundrug Co SWOT Analysis

Strengths

Sundrug Co Ltd has several key strengths that contribute to its success:

  • Strong brand reputation and recognition in the pharmaceutical industry.
  • Large customer base and loyal customer relationships.
  • Extensive product portfolio offering a wide range of pharmaceutical products.
  • Effective supply chain management ensuring timely and efficient distribution.
  • Established network of partnerships and collaborations for research and development.

Weaknesses

Although Sundrug Co Ltd has achieved significant success, it also faces certain weaknesses:

  • Relatively high production costs compared to some competitors.
  • Dependence on specific suppliers for certain raw materials.
  • Limited presence in international markets, thus missing out on potential growth opportunities.
  • Slow response to market trends and dynamic customer demands.
  • Inadequate marketing strategies to effectively promote the brand.

Opportunities

Sundrug Co Ltd can seize various opportunities to further enhance its position:

  • Expansion into emerging markets with growing healthcare sectors.
  • Development of innovative pharmaceutical solutions to address evolving healthcare needs.
  • Mergers and acquisitions to gain access to new technologies and products.
  • Collaboration with research institutions to drive advancements in pharmaceutical research.
  • Increased investment in digital technologies to improve operational efficiency.

Threats

Sundrug Co Ltd should be mindful of the following potential threats:

  • Intense competition from both established pharmaceutical companies and emerging startups.
  • Stringent regulatory requirements and increasing scrutiny on pharmaceutical safety.
  • Rising raw material costs and potential supply chain disruptions.
  • Changes in healthcare policies and government regulations impacting market dynamics.
  • Negative publicity or product recalls that can damage the brand reputation.

Sundrug Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sundrug Co historical P/E ratio, EBIT multiple, and P/S ratio

Sundrug Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sundrug Co shares outstanding

The number of shares of Sundrug Co was 116.96 M in 2025. This indicates how many shares Sundrug Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
116.92 M Stocks
Jan 1, 2022
116.92 M Stocks
Jan 1, 2023
116.93 M Stocks
Jan 1, 2024
116.94 M Stocks
Jan 1, 2025
116.96 M Stocks
Jan 1, 2026 (e)
116.96 M Stocks
Jan 1, 2027 (e)
116.96 M Stocks
Jan 1, 2028 (e)
116.96 M Stocks

Sundrug Co stock splits

In Sundrug Co's history, there have been no stock splits.

Sundrug Co Dividend History

35 years of dividend payments · 8 consecutive increases

YearAnnual DividendYoY ChangePayments
202666.00JPYYTD—1×
Mar 30, 202666.00JPY↑ 1.5%1/1
2025130.00JPY↑ 6.6%2×
Mar 28, 202565.00JPY 0.0%1/2
Sep 29, 202565.00JPY 0.0%2/2
2024122.00JPY↑ 14.0%2×
2023107.00JPY↑ 24.4%2×
202286.00JPY↑ 22.9%2×
202170.00JPY↑ 1.4%2×
202069.00JPY↑ 3.0%2×
201967.00JPY↑ 1.5%2×
201866.00JPY↑ 21.1%2×
201754.50JPY↓ 39.4%2×

Sundrug Co dividend history and estimates

In 2025, Sundrug Co paid a dividend amounting to 130.00 JPY. Dividend means that Sundrug Co distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
70.00 JPY
0.00 JPY
Jan 1, 2022
86.00 JPY
0.00 JPY
Jan 1, 2023
107.00 JPY
0.00 JPY
Jan 1, 2024
122.00 JPY
0.00 JPY
Jan 1, 2025
130.00 JPY
0.00 JPY
Jan 1, 2026
196.00 JPY
0.00 JPY
Jan 1, 2027 (e)
0.00 JPY
235.20 JPY
Jan 1, 2028 (e)
0.00 JPY
282.24 JPY

Sundrug Co dividend payout ratio

In 2025, Sundrug Co had a payout ratio of 49.45%. The payout ratio indicates the percentage of the company's profits that Sundrug Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
32.31 %
Jan 1, 2022
42.16 %
Jan 1, 2023
48.68 %
Jan 1, 2024
48.98 %
Jan 1, 2025
49.45 %
Jan 1, 2026 (e)
73.01 %
Jan 1, 2027 (e)
81.36 %
Jan 1, 2028 (e)
91.04 %

Current Sundrug Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.85 %
Buy
69.23 % (9)
Hold
30.77 % (4)
Sell
0.00 % (0)
12M Price Target
5,508.00
Last Price
3,726.00
Currency
JPY
12M Return Potential
47.83 %
LTM Return
0 %

Sundrug Co Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/13/202451.24JPY-188.31 BJPY-2024 Q4
2/12/202470.95JPY-196.88 BJPY-2024 Q3
8/12/202258.21JPY-177.35 BJPY-2023 Q1
5/13/202255.12JPY-163.87 BJPY-2022 Q4
2/14/202256.27JPY-170.75 BJPY-2022 Q3
11/12/202155.23JPY-165.76 BJPY-2022 Q2
8/12/2021-JPY-164.13 BJPY-2022 Q1
5/14/2021-JPY-157.44 BJPY-2021 Q4
2/10/2021-JPY-166.74 BJPY-2021 Q3
11/11/2020-JPY-161.09 BJPY-2021 Q2

EESG©

Eulerpool ESG Scorecard© for the Sundrug Co stock

55/100
66
Environment
59
Social
41
Governance
E

Environment

20
Scope 1 - Direct Emissions24,916
Scope 2 - Indirect emissions from purchased energy157,146
Scope 3 - Indirect emissions within the value chain2,433,338
Total CO₂ emissions182,062
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees62.2
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sundrug Co shareholder structure

% Name
2.14725%
Nomura Asset Management Co., Ltd.
Nomura Asset Management Co., Ltd.
1.83184%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.20202%
Nikko Asset Management Co., Ltd.
Nikko Asset Management Co., Ltd.
1.00211%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.88462%
Daiwa Asset Management Co., Ltd.
Daiwa Asset Management Co., Ltd.
0.65311%
Columbia Threadneedle Investments (US)
Columbia Threadneedle Investments (US)
...

Sundrug Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
58.0%
Float Shares
-
Shares Outstanding
-

Sundrug Co Executives and Management Board

10 members · avg. age 60 · 20 % women

HS

Mr. Hiroshi Sadakata (53)

President, Chief Executive Officer, Chairman of Subsidiary, Representative Director · since 2008

165.00 M JPY

Management

KU

Mr. Koichi Ura

Executive Officer, Chief Director of Sales

–
YK

Mr. Yoshinobu Kato

Executive Officer, Director of Administration

–
KY

Mr. Kazuhiro Yamauchi

Executive Officer, Chief Director of Product

–

Board of Directors

NT

Mr. Naoki Tada (61)

Chairman, Director · since 2001

–
YS

Mr. Yoshimitsu Sakai (59)

Director of Store Development, Director · since 2010

–
TT

Mr. Takashi Tada (55)

Director · since 2017

–
MM

Mr. Masato Matsumoto (67)

Independent Director

–
RS

Ms. Ritsuko Saito (59)

Independent Director

–
TT

Ms. Tomoko Tsuji (67)

Independent Director

–

Sundrug Co Supply Chain

Sundrug Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Nameβ 1YTrend
1
Arcs
Supplier·Customer·Food & Staples Retailing·JP
0.21
0.55
0.74
0.67
0.86
0.62
0.98
#Nameβ 1YTrend
1
Mitsubishi UFJ Financial Group
Supplier·Customer·Banks·JP
0.30
-0.24
-0.43
-0.32
-0.72
-0.77
-1.22
2
Nippon Systemware
Supplier·Software·JP
-0.12
-0.51
-0.69
-0.38
0.56
-0.38
—

Frequently asked questions about Sundrug Co

The business model of Sundrug Co Ltd revolves around operating a chain of retail pharmacies in Japan. Sundrug Co Ltd focuses on providing a wide range of pharmaceutical products, health supplements, and personal care items to its customers. The company also emphasizes offering quality customer service and convenient in-store experiences to enhance customer satisfaction. By prioritizing accessibility, Sundrug Co Ltd aims to cater to the healthcare needs of the local community while maintaining its competitive position in the pharmaceutical retail industry.

Sundrug Co Ltd is primarily active in the pharmaceutical and retail industries.

The main competitors of Sundrug Co Ltd in the market include companies such as Matsumotokiyoshi Holdings Co Ltd, Tomod's Inc, and Cocokara Fine Inc. These companies operate in the same retail pharmaceutical industry and provide similar products and services to customers. Sundrug Co Ltd faces competition in terms of pricing, product variety, and customer service from these industry rivals. However, Sundrug Co Ltd has managed to establish a strong presence and maintain its competitive edge through its extensive network of stores, strategic partnerships, and commitment to customer satisfaction.

Sundrug Co Ltd is a leading pharmaceutical company based in Japan. With a rich history dating back to its establishment in 2002, Sundrug has grown to become a trusted name in the healthcare industry. The company operates a chain of retail pharmacies, providing a wide range of prescription drugs, over-the-counter medications, and health products. Sundrug Co Ltd aims to improve the well-being of its customers by delivering high-quality healthcare services and products. With its commitment to innovation and customer satisfaction, Sundrug continues to expand its presence in the market, making it a reliable choice for all your pharmaceutical needs.

Some significant milestones achieved by Sundrug Co Ltd include its establishment in 1990, successful expansion into various regions of Japan, and becoming one of the leading retail pharmacy chains in the country. The company has consistently focused on quality healthcare services and customer satisfaction. Sundrug Co Ltd has also cultivated strategic partnerships with major pharmaceutical companies, allowing them to offer a wide range of medicines and healthcare products. With a strong emphasis on innovation and community support, Sundrug Co Ltd continues to strengthen its presence in the Japanese healthcare industry.

Sundrug Co Ltd, a leading pharmaceutical company, primarily operates in Japan. With a strong market presence, Sundrug serves customers across various regions in Japan, including Tokyo, Osaka, and Hokkaido. As one of the largest drugstore chains in the country, Sundrug focuses on offering a wide range of medical products and healthcare services to its customers. With its extensive network of stores, Sundrug aims to provide convenient access to quality healthcare solutions for people throughout Japan.

Sundrug Co Ltd is a leading company that upholds strong values and corporate philosophy. They prioritize customer satisfaction by providing high-quality products and services. Sundrug Co Ltd aims to contribute to society through their commitment to health and wellness. Their core values include integrity, professionalism, and innovation. With a focus on teamwork and continuous improvement, Sundrug Co Ltd actively seeks to meet the diverse needs of their customers. By adhering to their corporate philosophy of contributing to a healthy and vibrant society, Sundrug Co Ltd has established a reputable name in the market.

Analysts currently set an average price target of 5,319.87 JPY for the Sundrug Co stock (median: 5,508.00 JPY), implying +42.8 % versus the latest price. The consensus is based on 13 analyst ratings.

Sundrug Co Analyst Price Targets 2026

13 analysts currently rate the Sundrug Co stock: 9 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Sundrug Co to generate revenue of 841.98 B JPY and earnings per share of 268.44 JPY.

Sundrug Co Analyst Price Targets 2026

Converted at the current exchange rate, the Sundrug Co share trades at 20.43 EUR (3,726.00 JPY).

Sundrug Co Ltd is a Japanese company that specializes in selling pharmaceuticals, medical devices, beauty products, and household items. The company operates both retail and wholesale stores to distribute its products on a wide basis.

The expected revenue of Sundrug Co is 841.98 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sundrug Co is 31.40 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sundrug Co is currently 13.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sundrug Co stock.

The price-to-sales ratio (P/S) of Sundrug Co is currently 0.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sundrug Co stock.

The Eulerpool Quality Score for Sundrug Co is 8/10.

The ISIN of Sundrug Co is JP3336600006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sundrug Co is 895861. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sundrug Co is 9989.T. The ticker symbol is used to trade Sundrug Co shares on the stock exchange.

Over the past 12 months, Sundrug Co paid a dividend of 130.00 JPY . This corresponds to a dividend yield of about 3.49 %. For the coming 12 months, Sundrug Co is expected to pay a dividend of 235.20 JPY.

The current dividend yield of Sundrug Co is 3.49 %.

Sundrug Co pays a dividend, distributed in the months of , , , .

Sundrug Co paid dividends every year for the past 34 years.

For the upcoming 12 months, dividends amounting to 235.20 JPY are expected. This corresponds to a dividend yield of 6.31 %.

Sundrug Co is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of Sundrug Co from amounting to 66 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Sundrug Co distributed 107 JPY as dividends.

The dividends of Sundrug Co are distributed in JPY.

All fundamentals and in-depth analysis of Sundrug Co

Our stock analysis for Sundrug Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sundrug Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sundrug Co Stock
Sundrug Co Revenue→
Sundrug Co Stock
Sundrug Co Net Income→
Sundrug Co Stock
Sundrug Co P/E→
Sundrug Co Stock
Sundrug Co P/S→
Sundrug Co Stock
Sundrug Co EBIT→
Sundrug Co Stock
Sundrug Co Dividend→
Sundrug Co Stock
Sundrug Co Directors Dealings→
Sundrug Co Stock
Sundrug Co Stocks→
Sundrug Co Stock
Sundrug Co Market capitalization→
Sundrug Co Stock
Sundrug Co Debt→
Sundrug Co Stock
Sundrug Co Liabilities→
Sundrug Co Stock
Sundrug Co Equity→
Sundrug Co Stock
Sundrug Co AAQS→
Sundrug Co Stock
Sundrug Co Employees→
Sundrug Co Stock
Sundrug Co ROE→
Sundrug Co Stock
Sundrug Co ROA→
Sundrug Co Stock
Sundrug Co ROCE→
Sundrug Co Stock
Sundrug Co News→
Sundrug Co Stock
Sundrug Co Analyst Price Targets→

Non-cyclical consumption Stocks

Sunil Agro FoodsSundrop BrandsSunjin CoSun Vending Technology PCLSunjuice Holdings CoSun RetailSunMoon Food CompanySun Art Retail GroupSunsweet PCLSumber Tani Agung Resources Tbk PTSuntory Beverage & FoodSumber Alfaria Trijaya Tbk PTAll Stocks A–Z →